Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Multiple Sclerosis

Free Subscription 24.11.2025 1 Arch Phys Med Rehabil 2 BMC Neurol 2 Brain 1 Can J Neurol Sci 5 J Neurol 2 J Neurol Sci 1 Nat Rev Neurol 3 PLoS One 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Phys Med Rehabil

1. PLOW M, Packer T, Mathiowetz VG, Van Denend T, et al
   A Non-Inferiority Randomized Clinical Trial Comparing Three Delivery Formats of a Rehabilitation Intervention to Reduce Fatigue among People with Multiple Sclerosis.
   Arch Phys Med Rehabil. 2025 Nov 14:S0003-9993(25)01034.
   PubMed         Abstract available
   
   

   
   BMC Neurol

2. JAKI R, Al-Frejat Z, Bitar Z
   Tumefactive demyelinating lesions: a case report and literature review.
   BMC Neurol. 2025;25:475.
   PubMed         Abstract available
   
   
3. TOTUK O, Turkkol M, Yadi F, Gudek HC, et al
   Sexual dysfunction in multiple sclerosis: prevalence, risk factors, and impact on quality of life in a large cohort study.
   BMC Neurol. 2025;25:468.
   PubMed         Abstract available
   
   

   
   Brain

4. FEINSTEIN A, Bar-Or A, Benedict RHB, Filippi M, et al
   Is multiple sclerosis-related depression different from depression in general? The data for and against.
   Brain. 2025 Sep 9:awaf319. doi: 10.1093.
   PubMed         Abstract available
   
   
5. MACESKI AM, Benkert P, Einsiedler M, Schaedelin S, et al
   GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
   Brain. 2025 Nov 14:awaf433. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Can J Neurol Sci

6. GLENNIE J, Strasser L, Ciftci B, Johnstone J, et al
   Equity of access to disease modifying therapy for pediatric multiple sclerosis: a survey of Canadian prescribers.
   Can J Neurol Sci. 2025 Nov 21:1-9. doi: 10.1017/cjn.2025.10479.
   PubMed        
   
   

   
   J Neurol

7. LADEIRA F, Nobrega C, Cerqueira J
   Correction: Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
   J Neurol. 2025;272:768.
   PubMed        
   
   
8. MARTIRE MS, Gattuso I, Vezzulli P, Guerrieri S, et al
   Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.
   J Neurol. 2025;272:773.
   PubMed        
   
   
9. MONSCHEIN T, Untersteiner H, Ponleitner M, Krajnc N, et al
   Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).
   J Neurol. 2025;272:774.
   PubMed         Abstract available
   
   
10. TEDONE N, Grosselle M, Portaccio E, Amato MP, et al
    The brief repeatable battery of neuropsychological test (BRB-N) version B: update of Italian normative data.
    J Neurol. 2025;272:776.
    PubMed         Abstract available
    
    
11. YANG X, Li F, Zhe J, Zhang Z, et al
    Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing-remitting multiple sclerosis: insights into cellular composition and immune dynamics.
    J Neurol. 2025;272:778.
    PubMed         Abstract available
    
    

    
    J Neurol Sci

12. CWAJNA M, Hamouda AM, Kendall N, Ghozy S, et al
    Factors influencing timeliness of reporting results from multiple sclerosis related clinical trials to ClinicalTrials.gov.
    J Neurol Sci. 2025;479:123744.
    PubMed         Abstract available
    
    
13. GELISSEN LMY, Hogenboom L, Toorop AA, Strijbis EMM, et al
    Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.
    J Neurol Sci. 2025;479:125652.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

14. BECKER J, Pitombeira MS, Rojas JI
    Epidemiology and characteristics of multiple sclerosis in Latin America.
    Nat Rev Neurol. 2025 Nov 17. doi: 10.1038/s41582-025-01160.
    PubMed         Abstract available
    
    

    
    PLoS One

15. SURESHKUMAR A, Simpson R, Bayley M, Kastner M, et al
    The use of implementation strategies to promote the uptake of psychological therapies among people with multiple sclerosis: A scoping review protocol.
    PLoS One. 2025;20:e0337105.
    PubMed         Abstract available
    
    
16. TABATABAEE S, Eissazade N, Mirzaasgari Z, Tabatabaee SM, et al
    Trans-orbital sonography of the optic nerve in multiple sclerosis.
    PLoS One. 2025;20:e0336564.
    PubMed         Abstract available
    
    
17. SALMAN F, Bergsland N, Dwyer MG, Reeves JA, et al
    Impact of processing and analysis methodology on thalamic susceptibility assessment in multiple sclerosis.
    PLoS One. 2025;20:e0332478.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

18. RICIGLIANO VAG, Stankoff B
    In vivo molecular imaging of brain tissue pathology in presymptomatic multiple sclerosis.
    Rev Neurol (Paris). 2025;181:847-851.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.